Yesterday, February 14, 2017, Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) issued a statement that it would be reviewing the safety of Uptravi after the deaths of five patients in France who were taking the drug. Uptravi (selexipag) is used as a long-term treatment for pulmonary arterial hypertension, … [Read more...]